Skip to main content

2023 | OriginalPaper | Buchkapitel

16. Enuresis und funktionelle Harninkontinenz

verfasst von : Prof. Dr. med. Alexander von Gontard

Erschienen in: Neuro-/Psychopharmaka im Kindes- und Jugendalter

Verlag: Springer Berlin Heidelberg

Zusammenfassung

Enuresis nocturna wird als Einnässen im Schlaf, funktionelle Harninkontinenz als Einnässen tags ab einem Alter von 5 Jahren nach Ausschluss organischer Ursachen definiert. Viele verschiedene Subtypen können differenziert werden. Eine genaue Diagnostik ist für eine spezifische, wirksame Therapie entscheidend. Für alle Formen der Enuresis nocturna und der funktionellen Harninkontinenz sind symptomorientierte, nichtpharmakologische Interventionen wegen der besseren Wirksamkeit zu bevorzugen. Eine Indikation zur Pharmakotherapie ergibt sich nur bei der Enuresis nocturna (vor allem mit Desmopressin), bei der Dranginkontinenz (Anticholinergika) und in den seltenen Fällen der Lachinkontinenz (Psychostimulanzien). Komorbide psychische Störungen, die 20–40 % der Kinder mit Enuresis und/oder Harninkontinenz betreffen, sind zu beachten.
Literatur
Zurück zum Zitat Alloussi S, Mürtz G, Braun R et al. (2009) Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxbutinine in children with urge incontinence due to overactive bladder: results of a multicentre observational cohort study. BJU Int 106:550–556PubMedCrossRef Alloussi S, Mürtz G, Braun R et al. (2009) Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxbutinine in children with urge incontinence due to overactive bladder: results of a multicentre observational cohort study. BJU Int 106:550–556PubMedCrossRef
Zurück zum Zitat Austin P, Bauer S, Bower W et al. (2016) The standardization of terminology of lower urinary tract function in children and adolescents: update report from the standardization committee of the international children’s continence society (ICCS). Neurourol Urodyn 35:471–481PubMedCrossRef Austin P, Bauer S, Bower W et al. (2016) The standardization of terminology of lower urinary tract function in children and adolescents: update report from the standardization committee of the international children’s continence society (ICCS). Neurourol Urodyn 35:471–481PubMedCrossRef
Zurück zum Zitat Barroso U, Tourinho R, Lordelo P, Hoebeke P, Chase J (2011) Electrical stimulation for lower urinary tract dysfunction in children: a systematic review of the literature. Neurolurol Urodynam 30:1429–1436CrossRef Barroso U, Tourinho R, Lordelo P, Hoebeke P, Chase J (2011) Electrical stimulation for lower urinary tract dysfunction in children: a systematic review of the literature. Neurolurol Urodynam 30:1429–1436CrossRef
Zurück zum Zitat Berry AK, Zderik S, Carr M (2009) Methylphenidate for giggle incontinence. J Urol 182(4 Suppl):2028–2032PubMedCrossRef Berry AK, Zderik S, Carr M (2009) Methylphenidate for giggle incontinence. J Urol 182(4 Suppl):2028–2032PubMedCrossRef
Zurück zum Zitat Biederman J, Thisted RA, Greenhill LL, Ryan ND (1995) Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year-old children. J Clin Psychiatry 56:87–93PubMed Biederman J, Thisted RA, Greenhill LL, Ryan ND (1995) Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year-old children. J Clin Psychiatry 56:87–93PubMed
Zurück zum Zitat Blais AS, Nadeau G, Moore K, Genois L, Bolduc S (2016) Prosepctive pilot study of mirabegron in pediatric patients with overactive bladder. Eur Urol 70:9–13PubMedCrossRef Blais AS, Nadeau G, Moore K, Genois L, Bolduc S (2016) Prosepctive pilot study of mirabegron in pediatric patients with overactive bladder. Eur Urol 70:9–13PubMedCrossRef
Zurück zum Zitat Bolduc S, Moore K, Nadeau G et al. (2010) Prospective open label study of solifenacin for overactive bladder in children. J Urol 184(4 Suppl):1668–1673PubMedCrossRef Bolduc S, Moore K, Nadeau G et al. (2010) Prospective open label study of solifenacin for overactive bladder in children. J Urol 184(4 Suppl):1668–1673PubMedCrossRef
Zurück zum Zitat Chang JH, Lee KY, Kim TB et al. (2011) Clinical and urodynamic effect of methylphenidate for the treatment of giggle incontinence. Neurourol Urodynam 30:1338–1342CrossRef Chang JH, Lee KY, Kim TB et al. (2011) Clinical and urodynamic effect of methylphenidate for the treatment of giggle incontinence. Neurourol Urodynam 30:1338–1342CrossRef
Zurück zum Zitat Claßen M, von Gontard A et al (2021) S2k-Leitlinie Funktionelle (nicht-organische) Obstipation und Stuhlinkontinenz im Kindes- und Jugendalter (AWMF Registernummer 068-019) (AWMF-online) Claßen M, von Gontard A et al (2021) S2k-Leitlinie Funktionelle (nicht-organische) Obstipation und Stuhlinkontinenz im Kindes- und Jugendalter (AWMF Registernummer 068-019) (AWMF-online)
Zurück zum Zitat De Bruyne P, De Guchtenare A, Van Herzeele Ch et al. (2014) Pharmacokinetics of desmopressin administered as tablet and oral lyophilisate formulation in children with monosymptomatic nocturnal enuresis. Eur J Pediatr 173:223–228PubMedCrossRef De Bruyne P, De Guchtenare A, Van Herzeele Ch et al. (2014) Pharmacokinetics of desmopressin administered as tablet and oral lyophilisate formulation in children with monosymptomatic nocturnal enuresis. Eur J Pediatr 173:223–228PubMedCrossRef
Zurück zum Zitat Equit M, Sambach H, Niemczyk J, von Gontard A (2013) Ausscheidungsstörungen bei Kindern und Jugendlichen – ein Therapieprogramm zur Blasen- und Darmschulung. Hogrefe, Göttingen Equit M, Sambach H, Niemczyk J, von Gontard A (2013) Ausscheidungsstörungen bei Kindern und Jugendlichen – ein Therapieprogramm zur Blasen- und Darmschulung. Hogrefe, Göttingen
Zurück zum Zitat Falkai P, Wittchen H-U (2015) American Psychiatric Association. Diagnostisches und Statistisches Manual Psychischer Störungen DSM-5. Hogrefe, Göttingen Falkai P, Wittchen H-U (2015) American Psychiatric Association. Diagnostisches und Statistisches Manual Psychischer Störungen DSM-5. Hogrefe, Göttingen
Zurück zum Zitat Fernandes L, Martin D, Hum S (2018) A case of the giggles: diagnosis and management of giggle incontinence. Can Fam Physician 64:445–447PubMedPubMedCentral Fernandes L, Martin D, Hum S (2018) A case of the giggles: diagnosis and management of giggle incontinence. Can Fam Physician 64:445–447PubMedPubMedCentral
Zurück zum Zitat Ferring (2011) Fachinformation Minirin Lyophilisat. Rote Liste Service GmbH, Fachinfoservice, Berlin Ferring (2011) Fachinformation Minirin Lyophilisat. Rote Liste Service GmbH, Fachinfoservice, Berlin
Zurück zum Zitat Franco I (2007) Overactive bladder in children. Part I: pathophysiology. J Urol 178:761–768PubMedCrossRef Franco I (2007) Overactive bladder in children. Part I: pathophysiology. J Urol 178:761–768PubMedCrossRef
Zurück zum Zitat Franco I, Austin P, Bauer S, von Gontard A, Homsy Y (ed) (2015) Pediatric incontinence: evaluation and clinical management. Wiley-Blackwell, Oxford, Hoboken Franco I, Austin P, Bauer S, von Gontard A, Homsy Y (ed) (2015) Pediatric incontinence: evaluation and clinical management. Wiley-Blackwell, Oxford, Hoboken
Zurück zum Zitat Franco I, Hiebeke P, Baka-Ostrowska M et al. (2020) Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from the phase 3 prospective open-label studies. J Ped Urol 16:180.e1–180.e8CrossRef Franco I, Hiebeke P, Baka-Ostrowska M et al. (2020) Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from the phase 3 prospective open-label studies. J Ped Urol 16:180.e1–180.e8CrossRef
Zurück zum Zitat Gepertz S, Neveus T (2004) Imipramine for therapy resistant enuresis: a retrospective evaluation. J Urol 171:2607–2610PubMedCrossRef Gepertz S, Neveus T (2004) Imipramine for therapy resistant enuresis: a retrospective evaluation. J Urol 171:2607–2610PubMedCrossRef
Zurück zum Zitat Hjälmas K, Hellström A, Mogren G, Läckgren G, Stenberg A (2001) The overactive bladder in children: a potential future indication for tolterodine. BJU Intern 87:569–574CrossRef Hjälmas K, Hellström A, Mogren G, Läckgren G, Stenberg A (2001) The overactive bladder in children: a potential future indication for tolterodine. BJU Intern 87:569–574CrossRef
Zurück zum Zitat Hoebeke P, De Pooter J, De Caestecker K et al. (2009) Solifenacin for therapy resistant overactive bladder. J Urol 182:2040–2044PubMedCrossRef Hoebeke P, De Pooter J, De Caestecker K et al. (2009) Solifenacin for therapy resistant overactive bladder. J Urol 182:2040–2044PubMedCrossRef
Zurück zum Zitat Houts AC, Berman JS, Abramson H (1994) Effectiveness of psychological and pharmalogical treatments for nocturnal enuresis. J Consult Clin Psychol 62:737–745PubMedCrossRef Houts AC, Berman JS, Abramson H (1994) Effectiveness of psychological and pharmalogical treatments for nocturnal enuresis. J Consult Clin Psychol 62:737–745PubMedCrossRef
Zurück zum Zitat Joinson C, Heron J, von Gontard A, the ALSPAC study team (2006) Psychological problems in children with daytime wetting. Pediatrics 118:1985–1993PubMedCrossRef Joinson C, Heron J, von Gontard A, the ALSPAC study team (2006) Psychological problems in children with daytime wetting. Pediatrics 118:1985–1993PubMedCrossRef
Zurück zum Zitat Juul KV, Van Herzele C, De Bruyne P et al. (2013) Desmopressin melt improves response and compliance compared with tablet in treatment of primary monosymptomatic enuresis. Eur J Pediatr 172:1235–1242PubMedPubMedCentralCrossRef Juul KV, Van Herzele C, De Bruyne P et al. (2013) Desmopressin melt improves response and compliance compared with tablet in treatment of primary monosymptomatic enuresis. Eur J Pediatr 172:1235–1242PubMedPubMedCentralCrossRef
Zurück zum Zitat Kilic N, Balkan E, Akgoz S, Sen N, Dogruyol H (2006) Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor overactivity. Int J Urol 13:105–108PubMedCrossRef Kilic N, Balkan E, Akgoz S, Sen N, Dogruyol H (2006) Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor overactivity. Int J Urol 13:105–108PubMedCrossRef
Zurück zum Zitat Kuwertz-Bröking E, von Gontard A (2021) S2k-Leitlinie Enuresis und nicht-organische (funktionelle) Harninkontinenz bei Kindern und Jugendlichen (AWMF Registriernummer 028-026) (AWMF online) Kuwertz-Bröking E, von Gontard A (2021) S2k-Leitlinie Enuresis und nicht-organische (funktionelle) Harninkontinenz bei Kindern und Jugendlichen (AWMF Registriernummer 028-026) (AWMF online)
Zurück zum Zitat Kwak KW, Lee YS, Park KH, Baek M (2010) Efficacy of Desmopressin and enuresis alarm as first and second line treatment for primary monosymptomatic nocturnal enuresis: prospective randomized crossover study. J Urol 185:2521–2526CrossRef Kwak KW, Lee YS, Park KH, Baek M (2010) Efficacy of Desmopressin and enuresis alarm as first and second line treatment for primary monosymptomatic nocturnal enuresis: prospective randomized crossover study. J Urol 185:2521–2526CrossRef
Zurück zum Zitat Lopez Pereira P, Miquelez C, Caffarati J, Estornell F, Anquera A (2003) Trospium chloride for the treatment of detrusor instablity in children. J Urol 170:1978–1981PubMedCrossRef Lopez Pereira P, Miquelez C, Caffarati J, Estornell F, Anquera A (2003) Trospium chloride for the treatment of detrusor instablity in children. J Urol 170:1978–1981PubMedCrossRef
Zurück zum Zitat Lundmark E, Neveus T (2009) Reboxetine in therapy-resistant enuresis: a retrospective evaluation. Scan J Urol Nephrol 43:365–368CrossRef Lundmark E, Neveus T (2009) Reboxetine in therapy-resistant enuresis: a retrospective evaluation. Scan J Urol Nephrol 43:365–368CrossRef
Zurück zum Zitat Marschall-Kehrel D, Feustel C, Persson de Geeter C et al. (2009) Treatment of propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results from a randomized placebo-controlled phase 3 clinical trial. Eur Urol 55:729–738PubMedCrossRef Marschall-Kehrel D, Feustel C, Persson de Geeter C et al. (2009) Treatment of propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results from a randomized placebo-controlled phase 3 clinical trial. Eur Urol 55:729–738PubMedCrossRef
Zurück zum Zitat Medhi B, Mittal N, Bansal D et al. (2013) Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/overactive bladder: a systematic review. Indian J Physiol Pharmacol 57:1511–1517 Medhi B, Mittal N, Bansal D et al. (2013) Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/overactive bladder: a systematic review. Indian J Physiol Pharmacol 57:1511–1517
Zurück zum Zitat Nevéus T, Fonseca E, Franco I et al. (2020) Management and treatment of nocturnal enuresis – an updated standardization document from the International Children’s Continence Society. J Pediatr Urol 16:10–19PubMedCrossRef Nevéus T, Fonseca E, Franco I et al. (2020) Management and treatment of nocturnal enuresis – an updated standardization document from the International Children’s Continence Society. J Pediatr Urol 16:10–19PubMedCrossRef
Zurück zum Zitat Neveus T, Tullus K (2008) Tolterodine and imipramine in refractory enuresis: a placebo-controlled cross-over study. Pediatr Nephrol 23:262–267CrossRef Neveus T, Tullus K (2008) Tolterodine and imipramine in refractory enuresis: a placebo-controlled cross-over study. Pediatr Nephrol 23:262–267CrossRef
Zurück zum Zitat Newgreen D, Bosman B, Hollestein-Havelaar A et al. (2017) Solifenacin in children and adolescents with overactive bladder: results of a phase 3 randomised clinical trial. Eur Urol 71(3):483–490PubMedCrossRef Newgreen D, Bosman B, Hollestein-Havelaar A et al. (2017) Solifenacin in children and adolescents with overactive bladder: results of a phase 3 randomised clinical trial. Eur Urol 71(3):483–490PubMedCrossRef
Zurück zum Zitat NICE clinical guideline 111 (2010) Nocturnal enuresis – the management of bedwetting in children and young people. National Institute for Health and Clinical Excellence, London NICE clinical guideline 111 (2010) Nocturnal enuresis – the management of bedwetting in children and young people. National Institute for Health and Clinical Excellence, London
Zurück zum Zitat Nijman RJ, Borgstein NG, Ellsworth P, Djurhuss JC (2005) Tolterodine treatment for children with symptoms or urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials. J Urol 173:1334–1339PubMedCrossRef Nijman RJ, Borgstein NG, Ellsworth P, Djurhuss JC (2005) Tolterodine treatment for children with symptoms or urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials. J Urol 173:1334–1339PubMedCrossRef
Zurück zum Zitat Nijman RJ, Borgstein NG, Ellsworth P, Siggard C (2007) Long-term tolerability of tolterodine extended release in children 5–11 years of age: results from a 12-month, open-label study. Eur Urol 52:1511–1516PubMedCrossRef Nijman RJ, Borgstein NG, Ellsworth P, Siggard C (2007) Long-term tolerability of tolterodine extended release in children 5–11 years of age: results from a 12-month, open-label study. Eur Urol 52:1511–1516PubMedCrossRef
Zurück zum Zitat Ohtomo Y (2017a) Atomoxetine ameliorates nocturnal enuresis with subclinical attention-deficit/hyperactivity disorder. Pediatr Int 59:181–184PubMedCrossRef Ohtomo Y (2017a) Atomoxetine ameliorates nocturnal enuresis with subclinical attention-deficit/hyperactivity disorder. Pediatr Int 59:181–184PubMedCrossRef
Zurück zum Zitat Ohtomo Y (2017b) Clonidine may have a beneficial effect on refractory nocturnal enuresis. Pediatr Int 59:711–713PubMedCrossRef Ohtomo Y (2017b) Clonidine may have a beneficial effect on refractory nocturnal enuresis. Pediatr Int 59:711–713PubMedCrossRef
Zurück zum Zitat Rovner ES (2004) Trospium chloride in the management of overactive bladder. Drugs 64:2443–2446CrossRef Rovner ES (2004) Trospium chloride in the management of overactive bladder. Drugs 64:2443–2446CrossRef
Zurück zum Zitat Schäfer SK, Niemczyk J, von Gontard A et al. (2017) Standard urotherapy as first-line intervention for daytime incontinence: a meta-analysis. Eur Child Adolesc Psychiatry 27:949–964PubMedCrossRef Schäfer SK, Niemczyk J, von Gontard A et al. (2017) Standard urotherapy as first-line intervention for daytime incontinence: a meta-analysis. Eur Child Adolesc Psychiatry 27:949–964PubMedCrossRef
Zurück zum Zitat Schatzberg AF, Cole JO, DeBattista C (2003) Manual of clinical psychopharmacology. American Psychiatric Publishing, Washington Schatzberg AF, Cole JO, DeBattista C (2003) Manual of clinical psychopharmacology. American Psychiatric Publishing, Washington
Zurück zum Zitat Sher PK, Reinberg Y (1996) Successful treatment of giggle incontinence with methylphenidate. J Urol 156:656–658PubMedCrossRef Sher PK, Reinberg Y (1996) Successful treatment of giggle incontinence with methylphenidate. J Urol 156:656–658PubMedCrossRef
Zurück zum Zitat Staskin D, Kay G, Tannenbaum C et al. (2010) Trospiumchloride has no effect on memory testing and is undectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 64:1294–1300PubMedCrossRef Staskin D, Kay G, Tannenbaum C et al. (2010) Trospiumchloride has no effect on memory testing and is undectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 64:1294–1300PubMedCrossRef
Zurück zum Zitat Sumner SR, Schuh KJ, Sutton VK, Lipetz R, Kelsey DK (2006) Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis. J Child Adolesc Psychopharmacol 16:699–671PubMedCrossRef Sumner SR, Schuh KJ, Sutton VK, Lipetz R, Kelsey DK (2006) Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis. J Child Adolesc Psychopharmacol 16:699–671PubMedCrossRef
Zurück zum Zitat van Kerrebroeck PEV (2002) Experience with the long-term use of desmopressin for nocturnal enuresis in children and adolescents. BJU Int 89:420–425PubMedCrossRef van Kerrebroeck PEV (2002) Experience with the long-term use of desmopressin for nocturnal enuresis in children and adolescents. BJU Int 89:420–425PubMedCrossRef
Zurück zum Zitat van Londen A, van Londen-Barensten M, van Son M, Mulder G (1995) Relapse rate and parental reaction after successful treatment of children suffering from nocturnal enuresis: a 2 ½ year follow-up of bibliotherapy. Beh Res Ther 33:309–311CrossRef van Londen A, van Londen-Barensten M, van Son M, Mulder G (1995) Relapse rate and parental reaction after successful treatment of children suffering from nocturnal enuresis: a 2 ½ year follow-up of bibliotherapy. Beh Res Ther 33:309–311CrossRef
Zurück zum Zitat von Gontard A (2013) The impact of DSM-5 and guidelines for assessment and treatment of elimination disorders. Eur Child Adolesc Psychiat 22(Suppl 1):S61–S67CrossRef von Gontard A (2013) The impact of DSM-5 and guidelines for assessment and treatment of elimination disorders. Eur Child Adolesc Psychiat 22(Suppl 1):S61–S67CrossRef
Zurück zum Zitat von Gontard A (2014) Klassifikation der Enuresis/Enkopresis in der DSM-5. Z Kinder Jugendpsychiatr Psychother 42:109–113CrossRef von Gontard A (2014) Klassifikation der Enuresis/Enkopresis in der DSM-5. Z Kinder Jugendpsychiatr Psychother 42:109–113CrossRef
Zurück zum Zitat von Gontard A (2018) Leitfaden Enuresis, 3. Aufl. Hogrefe, GöttingenCrossRef von Gontard A (2018) Leitfaden Enuresis, 3. Aufl. Hogrefe, GöttingenCrossRef
Zurück zum Zitat von Gontard A (2021) Ausscheidungsstörungen – Klassifikation und Definition nach ICD-11. Z Kinder Jugendpsychiatr Psychother 49:421–428CrossRef von Gontard A (2021) Ausscheidungsstörungen – Klassifikation und Definition nach ICD-11. Z Kinder Jugendpsychiatr Psychother 49:421–428CrossRef
Zurück zum Zitat von Gontard A, Equit M (2015) Comorbidity of ADHD and incontinence in children. Eur Child Adolesc Psychiat 24:127–140CrossRef von Gontard A, Equit M (2015) Comorbidity of ADHD and incontinence in children. Eur Child Adolesc Psychiat 24:127–140CrossRef
Zurück zum Zitat von Gontard A, Baeyens D, Van Hoecke E, Warzak W, Bachmann C (2011) Psychological and psychiatric issues in urinary and fecal incontinence. J Urol 185:1432–1437CrossRef von Gontard A, Baeyens D, Van Hoecke E, Warzak W, Bachmann C (2011) Psychological and psychiatric issues in urinary and fecal incontinence. J Urol 185:1432–1437CrossRef
Zurück zum Zitat Wright A, Haddad M (2017) Electroneurostimulation for the management of bladder bowel dysfunction in childhood. Eur J Ped Neurol 21:67–74CrossRef Wright A, Haddad M (2017) Electroneurostimulation for the management of bladder bowel dysfunction in childhood. Eur J Ped Neurol 21:67–74CrossRef
Zurück zum Zitat Yang St, Chua ME, Bauer St et al. (2018) Diagnosis and management of bladder bowel dysfunction in children with urinary tract infections: a position statement from the International Children’s Continence Society. Ped Nephrol 33:2207–2219CrossRef Yang St, Chua ME, Bauer St et al. (2018) Diagnosis and management of bladder bowel dysfunction in children with urinary tract infections: a position statement from the International Children’s Continence Society. Ped Nephrol 33:2207–2219CrossRef
Metadaten
Titel
Enuresis und funktionelle Harninkontinenz
verfasst von
Prof. Dr. med. Alexander von Gontard
Copyright-Jahr
2023
Verlag
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-662-65267-1_16

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).